BB&T Securities LLC Cuts Position in Pfizer, Inc. (PFE)
BB&T Securities LLC trimmed its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 21.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,091,252 shares of the biopharmaceutical company’s stock after selling 587,432 shares during the quarter. Pfizer makes up about 1.0% of BB&T Securities LLC’s investment portfolio, making the stock its 6th largest holding. BB&T Securities LLC owned approximately 0.13% of Pfizer worth $70,246,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Shine Investment Advisory Services Inc. bought a new position in shares of Pfizer in the second quarter worth approximately $102,000. D. Scott Neal Inc. boosted its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer in the first quarter worth approximately $121,000. Cascade Investment Advisors Inc. boosted its position in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,200 shares during the period. Finally, Perennial Advisors LLC boosted its position in shares of Pfizer by 7.9% in the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 376 shares during the period. Institutional investors own 69.34% of the company’s stock.
A number of equities analysts have weighed in on the stock. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, October 31st. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. Pfizer has a consensus rating of “Buy” and a consensus price target of $38.66.
Shares of Pfizer, Inc. (PFE) traded up $0.06 during trading hours on Friday, hitting $35.49. 6,397,307 shares of the company were exchanged, compared to its average volume of 14,047,984. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer, Inc. has a 12-month low of $30.51 and a 12-month high of $36.78. The company has a market capitalization of $211,217.66, a price-to-earnings ratio of 14.17, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the prior year, the business earned $0.61 earnings per share. Pfizer’s revenue for the quarter was up .9% on a year-over-year basis. equities research analysts anticipate that Pfizer, Inc. will post 2.6 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.
In related news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 366,557 shares of company stock worth $12,532,406. 0.06% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “BB&T Securities LLC Cuts Position in Pfizer, Inc. (PFE)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/bbt-securities-llc-cuts-position-in-pfizer-inc-pfe/1725967.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.